Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies

Dr. Emma Searle, Tomasz Knurowski, Sarah Gooding, Victoria Campbell, Sally Moore, Aristeidis Chaidos, Jennifer Travers, Thomas Creasey, Karen Clegg, Tim Somervaille, Charlotte Pawlyn

Blood (2025) 146 (Supplement 1): 8242.

https://doi.org/10.1182/blood-2025-8242

Published: 2025

Journal Articles

Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients

Blood (2025) 146 (Supplement 1): 98.

https://doi.org/10.1182/blood-2025-98

Published: 2025

Journal Articles

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4035.

https://doi.org/10.1182/blood-2025-4035

Published: 2025

Journal Articles

Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

Blood (2025) 146 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2025-2141

Published: 2025

Journal Articles

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

Jemma Larham, Elizabeth Knight, Lauren Campbell, Jessie Kaur, Oluremi Carty, Constantinos Koshiaris, I-Jun Lau, Joe Browning, Jaimal Kothari, Sarah Gooding, Anjan Thakurta, Udo Oppermann, Karthik Ramasamy

Blood (2025) 146 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2025-2185

Published: 2025

Journal Articles

ADAR1 in lenalidomide resistance: still immunomodulation?

Sarah Gooding

Blood (2025) 145 (11): 1104–1106.

https://doi.org/10.1182/blood.2024027539

Published: 2025

Journal Articles

A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Naser Ansari-Pour, Mohammad Kazeroun, Seyed Alireza Hasheminasab, Emma J Lyon, Bethan Hudson-Lund, Evie Fitzsimons, Gaurav Agarwal, Kara-Louise Royle, Matthew W. Jenner, Martin F Kaiser, Karthik Ramasamy, Kwee Yong, Eileen M Boyle, Sarah Gooding, Angela Hamblin, Anjan Thakurta

Blood (2024) 144 (Supplement 1): 1909.

https://doi.org/10.1182/blood-2024-207973

Published: 2024

Journal Articles

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Sarah Gooding, Chen-Yi Wang, Warren Baker, Edmund Watson, Simon Davis, Roman Fischer, Oliver McCallion, Joanna Hester, Fadi Issa, Srinivasa Rao, Nick Athanasou, Anjan Thakurta, Karthik Ramasamy, Chad C. Bjorklund, Michael Amatangelo, Anita K. Gandhi, Adam P Cribbs, Alessandro Lagana, Udo Oppermann

Blood (2024) 144 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2024-205264

Published: 2024

Journal Articles

Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Emma Searle, Victoria Campbell, Charlotte Pawlyn, Ceri Bygrave, Sarah Gooding, James Cavet, Matthew W. Jenner, Vivek Radhakrishnan, Steve Knapper, Dima el-Sharkawi, Jenny O'Nions, Tomasz Knurowski, Karen Clegg, Will Henry West, Debbie Haynes, Kris Frese, Tim Somervaille

Blood (2024) 144 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2024-199779

Published: 2024

Journal Articles

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Blood (2024) 144 (Supplement 1): 3333.

https://doi.org/10.1182/blood-2024-209772

Published: 2024

Journal Articles

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Naser Ansari-Pour, Mohammad Kazeroun, Evie Fitzsimons, Selina J Chavda, Alessandro Lagana, Erin Flynt, Udo Oppermann, Karthik Ramasamy, Kwee Yong, Sarah Gooding, Anjan Thakurta

Blood (2023) 142 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2023-190584

Published: 2023

Journal Articles

High Throughput Risk-Adapted Monoclonal Gammopathy Community Monitoring Program

Gaurav Agarwal, Lauren Campbell, Oluremi Carty, Sally Moore, Sarah Gooding, Jaimal Kothari, Julia Evans, Jemma Larham, Lisa Ferguson, Pamela Roberts, Elizabeth Bateman, Ross Sadler, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 5077.

https://doi.org/10.1182/blood-2023-190444

Published: 2023

Journal Articles

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, Khrystal McBean, Lisa Ferguson, Jemma Larham, Jaimal Kothari, Naser Ansari-Pour, Sally Moore, Eileen Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding

Blood (2023) 142 (Supplement 1): 644.

https://doi.org/10.1182/blood-2023-182734

Published: 2023

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Blood (2023) 142 (Supplement 1): 6715.

https://doi.org/10.1182/blood-2023-188697

Published: 2023

Journal Articles

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Naser Ansari-Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, Maria Ortiz Estevez, Konstantinos Mavrommatis, Brian Walker, Gareth Morgan, Nikhil Munshi, Herve Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (6): 620–633.

https://doi.org/10.1182/blood.2022017010

Published: 2023

Includes: Supplemental data

Journal Articles

Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients

Blood (2022) 140 (Supplement 1): 1679–1681.

https://doi.org/10.1182/blood-2022-164881

Published: 2022

Journal Articles

Artificial Intelligence-Based Quantitative and Topological Analysis of Plasma Cell Burden: A New Tool for the Assessment of Myeloma

Oliver C. Lomas, Daniel Royston, Hosuk Ryou, Alan Aberdeen, Korsuk Sirinukunwattana, Karthik Ramasamy, Sarah Gooding, Jemma Larham

Blood (2022) 140 (Supplement 1): 12603–12604.

https://doi.org/10.1182/blood-2022-158525

Published: 2022

Journal Articles

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, Kubra Karagoz, Ann Polonskaia, Mirian Salazar, Evie Fitzsimons, Korsuk Sirinukunwattana, Selina Chavda, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, Anjan Thakurta

Blood (2022) 140 (16): 1816–1821.

https://doi.org/10.1182/blood.2022015909

Published: 2022

Includes: Supplemental data

Journal Articles

A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2676.

https://doi.org/10.1182/blood-2021-148692

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies

Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

ADAR1 in lenalidomide resistance: still immunomodulation?

A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

High Throughput Risk-Adapted Monoclonal Gammopathy Community Monitoring Program

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients

Artificial Intelligence-Based Quantitative and Topological Analysis of Plasma Cell Burden: A New Tool for the Assessment of Myeloma

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only